Neogen Corporation — Form 10-Q Summary
Reporting period: Three months ended August 31, 2026; balance-sheet comparisons are to May 31, 2026. Amounts are in millions except per-share data. The unaudited filing covers Neogen’s Food Safety and Animal Safety businesses.
Financial performance and condition
- Revenue: $222.8, up 6.5% from $209.2. Food Safety revenue was $163.2, up 7.3%; Animal Safety was $59.6, up 4.4%. International revenue was $112.7 versus $107.1.
- Profitability: Gross profit was $105.5 versus $95.0; gross margin improved to 47.4% from 45.4%. Operating loss narrowed to $1.8 from $16.1. Net loss was $11.9, or $0.05 per diluted share, compared with net income of $36.3, or $0.17 per share.
- Cash flow: Operating cash flow was $12.9 versus $10.8. Capital spending was $8.2 versus $24.0. Cash declined $13.5 during the quarter to $172.0. Financing used $19.0, including $20.0 of debt repayment.
- Debt and liquidity: Gross debt was $780.0 at August 31, comprising a $385.0 term loan, $346.5 senior notes and $48.5 revolver borrowings; reported non-current debt, net of issuance costs, was $774.2. Cash was $172.0, and revolver availability was $199.9. The company reported compliance with financial covenants. It made a further $10.0 term-loan prepayment in September.
- Balance sheet: Total assets were $3,303.2 and total liabilities were $1,216.8. Current assets were $582.5 and current liabilities $149.5. Shares outstanding at quarter-end were 218.3 million.
Changes versus the prior comparable quarter
- Revenue increased by $13.6, primarily from business growth and favorable foreign exchange, partly offset by the prior divestiture of Cleaners and Disinfectants and discontinued products. Management cited stronger indicators and pathogen products, alongside prior-year distributor inventory adjustments and current-quarter order timing.
- Gross margin improved on higher volume, pricing and favorable currency effects, partly offset by duplicative costs while preparing to manufacture Petrifilm products internally.
- Operating expenses declined $3.8, with lower sales and marketing and general and administrative costs partly offset by higher R&D spending. Segment operating income rose to $23.8 from $11.7; corporate expense and eliminations remained substantial at $25.6.
- The prior-year quarter included a $76.4 gain on the Cleaners and Disinfectants sale, which materially lifted prior-year net income and investing cash flow. The current quarter included a $0.4 loss on final working-capital settlement for that sale; the potential earnout was not achieved. Current-quarter other income included a $2.8 gain from revaluing the CAPInnoVet milestone liability.
Outlook, risks and unusual items
- Outlook: No specific revenue or earnings guidance is provided. Management estimates fiscal 2027 capital expenditures of approximately $40.0. It expects the effects of identified operating and market issues to continue during fiscal 2027.
- Management commentary: The company describes a fiscal 2027 growth strategy centered on commercial execution, innovation and operational efficiency, with cost controls intended to support reinvestment. It reports early improvement in Food Safety commercial execution and continued improvement in sample-collection manufacturing inefficiencies. Animal Safety end-market indicators have improved, while supplier quality issues that affected fiscal 2026 have largely improved.
- Genomics divestiture: Neogen agreed to sell its Genomics business to Zoetis for $160.0, subject to customary closing conditions and approvals. Australian and New Zealand regulators moved their reviews into a second phase; the company expects those reviews to conclude by the end of December 2026. The business remains classified as held for sale, with $70.4 of assets and $7.3 of liabilities.
- Product recall and claims: A voluntary recall covers unexpired Vet HyCoat product lots following contamination findings. The FDA issued a Warning Letter on September 23, 2026. The company says loss from related claims is probable but cannot be reasonably estimated beyond insurance coverage; it recorded no product-claims loss accrual. One lawsuit was settled, and other demands and lawsuits remain. Management does not currently expect a material adverse effect, but outcomes remain uncertain.
- Other legal matters: A federal securities class action related to the 3M integration was dismissed with prejudice on August 10, 2026, and plaintiffs appealed on September 8. A separate securities action related to the 2022 3M transaction remains pending; a derivative action is stayed pending the appeal. The company cannot estimate potential losses for these matters.
- Operating and financial risks: Management cites inflation and input costs, tariffs and trade policy, elevated borrowing costs, mixed demand, geopolitical disruption, integration and manufacturing execution, and risks to pending divestitures. A Randolph, Wisconsin environmental remediation liability totals $0.9; costs could rise if the regulator requires a change in remediation approach.
- Controls: Management concluded disclosure controls were effective as of August 31, 2026 and reported no material change in internal control over financial reporting during the quarter.
Key investor verification points
- Track the Zoetis Genomics sale, regulatory reviews, timing and final proceeds.
- Monitor Vet HyCoat recall developments, FDA follow-up, insurance coverage, claims and any future accruals.
- Assess whether revenue growth and gross-margin gains persist after accounting for order timing, distributor inventory effects, divestitures and currency.
- Review progress in lowering corporate costs and manufacturing inefficiencies, while funding planned innovation and approximately $40.0 of fiscal 2027 capital spending.
- Verify debt repayment, interest costs, covenant headroom and available revolver capacity; the filing reports both gross debt of $780.0 and net non-current debt of $774.2.
- Follow the securities litigation appeal and the remaining securities and derivative proceedings.